tiprankstipranks
Vertex Pharmaceuticals (DE:VX1)
XETRA:VX1
Germany Market
VX1
Vertex Pharmaceuticals
RESEARCH TOOLSreports

Vertex Pharmaceuticals (VX1) Stock Forecast & Price Target

23 Followers
See the Price Targets and Ratings of:

VX1 Analyst Ratings

Strong Buy
25Ratings
Strong Buy
21 Buy
4 Hold
0 Sell
Based on 25 analysts giving stock ratings to
Vertex
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VX1 Stock 12 Month Forecast

Average Price Target

€474.63
▲(27.32% Upside)
Based on 25 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is €474.63 with a high forecast of €543.66 and a low forecast of €374.03. The average price target represents a 27.32% change from the last price of €372.80.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"329":"€329","544":"€544","382.75":"€382.8","436.5":"€436.5","490.25":"€490.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":543.6640218,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€543.66</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":474.633109578,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€474.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":374.0340618,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€374.03</span>\n  </div></div>","useHTML":true}}],"tickPositions":[329,382.75,436.5,490.25,544],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,389.3,401.17415552307693,413.04831104615386,424.9224665692308,436.7966220923077,448.6707776153846,460.54493313846154,472.41908866153847,484.2932441846154,496.1673997076923,508.04155523076923,519.9157107538462,531.789866276923,{"y":543.6640218,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,389.3,395.86408535215384,402.4281707043077,408.99225605646154,415.5563414086154,422.12042676076925,428.6845121129231,435.24859746507695,441.8126828172308,448.3767681693846,454.9408535215385,461.5049388736923,468.0690242258462,{"y":474.633109578,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,389.3,388.12569706153846,386.9513941230769,385.7770911846154,384.60278824615386,383.4284853076923,382.25418236923076,381.07987943076927,379.9055764923077,378.73127355384617,377.5569706153846,376.3826676769231,375.20836473846157,{"y":374.0340618,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":453.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":445.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":387.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":384.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":396.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":330.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":346.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":366.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":368.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":391.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 78,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":398,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":415,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 87,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":389.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€543.66Average Price Target€474.63Lowest Price Target€374.03
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on DE:VX1
Terence Flynn
Morgan Stanley
Morgan Stanley
€505.5→€519.07
Buy
39.23%
Upside
Reiterated
04/15/26
Morgan Stanley Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Bank of America Securities Analyst forecast on DE:VX1
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
€507.19
Buy
36.05%
Upside
Reiterated
04/15/26
Vertex Pharmaceuticals: Solid CF Franchise and Emerging Pipeline Support Buy Rating and Premium Valuation
Canaccord Genuity Analyst forecast on DE:VX1
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€374.03
Hold
0.33%
Upside
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ) and Vertex Pharmaceuticals (NASDAQ: VRTX)
RBC Capital Analyst forecast on DE:VX1
Brian Abrahams
RBC Capital
RBC Capital
€458.85
Buy
23.08%
Upside
Reiterated
04/07/26
Vertex Pharmaceuticals price target raised to $543 from $541 at RBC CapitalVertex Pharmaceuticals price target raised to $543 from $541 at RBC Capital
Erste Group Analyst forecast on DE:VX1
Hans Engel
Erste Group
Erste Group
―
Hold
―
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and Green Thumb Industries (Other OTC: GTBIF)
Wells Fargo Analyst forecast on DE:VX1
Mohit Bansal
Wells Fargo
Wells Fargo
€513.13→€466.48
Buy
25.13%
Upside
Reiterated
04/01/26
Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Biogen (NASDAQ: BIIB) and Vertex Pharmaceuticals (NASDAQ: VRTX)
BMO Capital Analyst forecast on DE:VX1
Evan Seigerman
BMO Capital
BMO Capital
€508.89
Buy
36.50%
Upside
Reiterated
03/27/26
Vertex Pharmaceuticals: Resilient CF Franchise and Advancing Pipeline Support Buy Rating Despite Label Headwinds
William Blair Analyst forecast on DE:VX1
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
03/26/26
Analysts Conflicted on These Healthcare Names: Vertex Pharmaceuticals (NASDAQ: VRTX), Pacira Pharmaceuticals (NASDAQ: PCRX) and Alnylam Pharma (NASDAQ: ALNY)
Stifel Nicolaus Analyst forecast on DE:VX1
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€395.24
Hold
6.02%
Upside
Assigned
03/25/26
Analysts Offer Insights on Healthcare Companies: Neurogene (NASDAQ: NGNE), Vertex Pharmaceuticals (NASDAQ: VRTX) and Sarepta Therapeutics (NASDAQ: SRPT)
Maxim Group Analyst forecast on DE:VX1
Naz Rahman
Maxim Group
Maxim Group
€487.69
Buy
30.82%
Upside
Upgraded
03/18/26
Vertex Pharmaceuticals upgraded to Buy from Hold at MaximVertex Pharmaceuticals upgraded to Buy from Hold at Maxim
Truist Financial Analyst forecast on DE:VX1
Joon Lee
Truist Financial
Truist Financial
€415.59→€445.28
Buy
19.44%
Upside
Reiterated
03/11/26
Vertex Pharmaceuticals price target raised to $525 from $490 at TruistVertex Pharmaceuticals price target raised to $525 from $490 at Truist
Needham Analyst forecast on DE:VX1
Joseph Stringer
Needham
Needham
€390.15
Hold
4.65%
Upside
Reiterated
03/10/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
H.C. Wainwright Analyst forecast on DE:VX1
Andrew Fein
H.C. Wainwright
H.C. Wainwright
€501.26→€543.66
Buy
45.83%
Upside
Assigned
03/10/26
Vertex Pharmaceuticals price target raised to $641 from $591 at H.C. WainwrightVertex Pharmaceuticals price target raised to $641 from $591 at H.C. Wainwright
Oppenheimer Analyst forecast on DE:VX1
Jay Olson
Oppenheimer
Oppenheimer
€458→€508.89
Buy
36.50%
Upside
Reiterated
03/10/26
Vertex Pharmaceuticals price target raised to $600 from $540 at OppenheimerVertex Pharmaceuticals price target raised to $600 from $540 at Oppenheimer
Citi Analyst forecast on DE:VX1
Geoff Meacham
Citi
Citi
€487.69→€496.17
Buy
33.09%
Upside
Reiterated
03/10/26
Vertex Pharmaceuticals price target raised to $585 from $575 at CitiVertex Pharmaceuticals price target raised to $585 from $575 at Citi
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on DE:VX1
Terence Flynn
Morgan Stanley
Morgan Stanley
€505.5→€519.07
Buy
39.23%
Upside
Reiterated
04/15/26
Morgan Stanley Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Bank of America Securities Analyst forecast on DE:VX1
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
€507.19
Buy
36.05%
Upside
Reiterated
04/15/26
Vertex Pharmaceuticals: Solid CF Franchise and Emerging Pipeline Support Buy Rating and Premium Valuation
Canaccord Genuity Analyst forecast on DE:VX1
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€374.03
Hold
0.33%
Upside
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ) and Vertex Pharmaceuticals (NASDAQ: VRTX)
RBC Capital Analyst forecast on DE:VX1
Brian Abrahams
RBC Capital
RBC Capital
€458.85
Buy
23.08%
Upside
Reiterated
04/07/26
Vertex Pharmaceuticals price target raised to $543 from $541 at RBC CapitalVertex Pharmaceuticals price target raised to $543 from $541 at RBC Capital
Erste Group Analyst forecast on DE:VX1
Hans Engel
Erste Group
Erste Group
―
Hold
―
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and Green Thumb Industries (Other OTC: GTBIF)
Wells Fargo Analyst forecast on DE:VX1
Mohit Bansal
Wells Fargo
Wells Fargo
€513.13→€466.48
Buy
25.13%
Upside
Reiterated
04/01/26
Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Biogen (NASDAQ: BIIB) and Vertex Pharmaceuticals (NASDAQ: VRTX)
BMO Capital Analyst forecast on DE:VX1
Evan Seigerman
BMO Capital
BMO Capital
€508.89
Buy
36.50%
Upside
Reiterated
03/27/26
Vertex Pharmaceuticals: Resilient CF Franchise and Advancing Pipeline Support Buy Rating Despite Label Headwinds
William Blair Analyst forecast on DE:VX1
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
03/26/26
Analysts Conflicted on These Healthcare Names: Vertex Pharmaceuticals (NASDAQ: VRTX), Pacira Pharmaceuticals (NASDAQ: PCRX) and Alnylam Pharma (NASDAQ: ALNY)
Stifel Nicolaus Analyst forecast on DE:VX1
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€395.24
Hold
6.02%
Upside
Assigned
03/25/26
Analysts Offer Insights on Healthcare Companies: Neurogene (NASDAQ: NGNE), Vertex Pharmaceuticals (NASDAQ: VRTX) and Sarepta Therapeutics (NASDAQ: SRPT)
Maxim Group Analyst forecast on DE:VX1
Naz Rahman
Maxim Group
Maxim Group
€487.69
Buy
30.82%
Upside
Upgraded
03/18/26
Vertex Pharmaceuticals upgraded to Buy from Hold at MaximVertex Pharmaceuticals upgraded to Buy from Hold at Maxim
Truist Financial Analyst forecast on DE:VX1
Joon Lee
Truist Financial
Truist Financial
€415.59→€445.28
Buy
19.44%
Upside
Reiterated
03/11/26
Vertex Pharmaceuticals price target raised to $525 from $490 at TruistVertex Pharmaceuticals price target raised to $525 from $490 at Truist
Needham Analyst forecast on DE:VX1
Joseph Stringer
Needham
Needham
€390.15
Hold
4.65%
Upside
Reiterated
03/10/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
H.C. Wainwright Analyst forecast on DE:VX1
Andrew Fein
H.C. Wainwright
H.C. Wainwright
€501.26→€543.66
Buy
45.83%
Upside
Assigned
03/10/26
Vertex Pharmaceuticals price target raised to $641 from $591 at H.C. WainwrightVertex Pharmaceuticals price target raised to $641 from $591 at H.C. Wainwright
Oppenheimer Analyst forecast on DE:VX1
Jay Olson
Oppenheimer
Oppenheimer
€458→€508.89
Buy
36.50%
Upside
Reiterated
03/10/26
Vertex Pharmaceuticals price target raised to $600 from $540 at OppenheimerVertex Pharmaceuticals price target raised to $600 from $540 at Oppenheimer
Citi Analyst forecast on DE:VX1
Geoff Meacham
Citi
Citi
€487.69→€496.17
Buy
33.09%
Upside
Reiterated
03/10/26
Vertex Pharmaceuticals price target raised to $585 from $575 at CitiVertex Pharmaceuticals price target raised to $585 from $575 at Citi
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

3 Months
xxx
Success Rate
21/30 ratings generated profit
70%
Average Return
+6.97%
reiterated a xxx
 rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +6.97% per trade.
1 Year
Cory KasimovEvercore ISI
Success Rate
22/32 ratings generated profit
69%
Average Return
+12.28%
reiterated a buy rating 2 months ago
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +12.28% per trade.
2 Years
xxx
Success Rate
26/32 ratings generated profit
81%
Average Return
+24.12%
reiterated a xxx
 rating last month
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 81.25% of your transactions generating a profit, with an average return of +24.12% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VX1 Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
0
0
0
Buy
58
78
76
87
55
Hold
12
10
7
12
15
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
70
88
83
99
70
In the current month, VX1 has received 55 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. VX1 average Analyst price target in the past 3 months is 474.63.
Each month's total comprises the sum of three months' worth of ratings.

VX1 Financial Forecast

VX1 Earnings Forecast

Next quarter’s earnings estimate for VX1 is €3.67 with a range of €2.60 to €4.43. The previous quarter’s EPS was €4.26. VX1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year VX1 has Performed in-line its overall industry.
Next quarter’s earnings estimate for VX1 is €3.67 with a range of €2.60 to €4.43. The previous quarter’s EPS was €4.26. VX1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year VX1 has Performed in-line its overall industry.

VX1 Sales Forecast

Next quarter’s sales forecast for VX1 is €2.56B with a range of €2.46B to €2.74B. The previous quarter’s sales results were €2.73B. VX1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year VX1 has Performed in-line its overall industry.
Next quarter’s sales forecast for VX1 is €2.56B with a range of €2.46B to €2.74B. The previous quarter’s sales results were €2.73B. VX1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year VX1 has Performed in-line its overall industry.

VX1 Stock Forecast FAQ

What is DE:VX1’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is 474.63.
    What is DE:VX1’s upside potential, based on the analysts’ average price target?
    Vertex Pharmaceuticals has 27.32% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Vertex Pharmaceuticals a Buy, Sell or Hold?
          Vertex Pharmaceuticals has a consensus rating of Strong Buy, which is based on 21 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Vertex Pharmaceuticals’s share price target?
            The average share price target for Vertex Pharmaceuticals is 474.63. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €543.66 ,and the lowest forecast is €374.03. The average share price target represents 27.32% Increase from the current price of €372.8.
              What do analysts say about Vertex Pharmaceuticals?
              Vertex Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 25 Wall Streets Analysts.
                How can I buy shares of Vertex Pharmaceuticals?
                To buy shares of DE:VX1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.